c
Contact Us

‪0161 504 8999‬

info@nasgp.org.uk

Nice | Empagliflozin in Type 2 Diabetes

5th June 2015 by Louise Hudman

Back

Nice | Empagliflozin in Type 2 Diabetes

This is a new guideline from Nice. Empagliflozin is a selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor, which blocks glucose reabsorption in the kidneys and so causes increased urinary excretion. For other SGLT-2 inhibitors have been approved by NICE, see my post about Dapagliflozin.

Empagliflozin use in Type 2 Diabetes

  • as a 2nd drug in combination with metformin if they
    • can not take sulphonylureas.
    • are at significant risk of hypoglycaemia or its consequences.
  • as a 3rd drug with metformin and either a sulphonylurea or a thiazolinedione.
  • in combination with insulin with or without other drugs.

Read more

No credit card details needed – it takes two minutes.

Join free trial

Login

Already a member? Login to view this content.

Login

"LocumDeck is so good and so intuitive that I am lost for words and utterly filled with glee.

It can send an email confirming the sessions that are booked and creates and emails invoices direct to the practice for you. These contain links to your beautifully laid out ‘credentials’ page with all your relevant documents, and a model contract that is all ready for you to accept or edit.

It automatically produces and sends the locum form A, and will produce locum form B. It also acts as the calendar... And it all happens automatically. It is really less than a minute to invoice and do the pension forms, with everything calculated perfectly."

Dr Annette Steele, GP

See the full list of features within our NASGP membership plans

Membership